Table 2

Rapid urine LAM test result during 6 months of anti-TB treatment

Baseline (N=90)2-Month follow-up (N=73)p Value (baseline vs 2 months)6-Month follow-up (N=50)p Value (baseline vs 6 months)
Rapid urine LAM positiveN (%)N (%)N (%)
 All participants29 (32.2)12 (16.4)*0.00095 (10.0)†0.004
 HIV+28 (34.1)12 (17.6)0.0025 (10.6)0.007
 HIV+ and CD4 ≥100/mm314 (25.5)4 (8.2)0.013 (8.6)0.11
 HIV+ and CD4 <100/mm314 (51.9)8 (42.1)0.252 (16.7)0.06
Rapid urine LAM gradeMean±SDMean±SDMean±SD
 All participants0.7±1.30.5±1.20.0050.2±0.70.006
 HIV+0.8±1.40.5±1.30.0070.2±0.80.008
 HIV+ and CD4 ≥100/mm30.5±1.00.2±0.80.0070.1±0.30.04
 HIV+ and CD4 <100/mm31.3±1.81.3±1.9‡0.310.5±1.40.08
  • *1 culture-negative participant with negative baseline rapid urinary LAM became positive at the 2-month follow-up visit.

  • †2 culture-positive participants with negative baseline rapid urinary LAM became positive at the 6-month follow-up visit.

  • ‡1 culture-positive participant with 1+ grade at baseline rapid urinary LAM became 3+ at the 2 month follow-up visit; this participant died during the study.

  • LAM, lipoarabinomannan; TB, tuberculosis.